Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-202-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$70,000.00
Profitability
Miscellaneous
Employees25
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions
What is Regulus Therapeutics' stock symbol?
Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."
How were Regulus Therapeutics' earnings last quarter?
Regulus Therapeutics Inc (NASDAQ:RGLS) posted its quarterly earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.92) by $0.06. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $7.01 million. Regulus Therapeutics had a negative return on equity of 671.46% and a negative net margin of 67,650.01%. View Regulus Therapeutics' Earnings History.
When is Regulus Therapeutics' next earnings date?
What price target have analysts set for RGLS?
5 Wall Street analysts have issued 1-year target prices for Regulus Therapeutics' stock. Their forecasts range from $0.50 to $2.00. On average, they expect Regulus Therapeutics' share price to reach $1.3333 in the next year. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Regulus Therapeutics.
What is the consensus analysts' recommendation for Regulus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regulus Therapeutics.
What are Wall Street analysts saying about Regulus Therapeutics stock?
Here are some recent quotes from research analysts about Regulus Therapeutics stock:
- 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (1/11/2019)
- 2. Needham & Company LLC analysts commented, "Regulus announced this morning another revision to the Sanofi collaboration agreement, in which Sanofi has been granted a WW exclusive license to RG-012. Sanofi will now assume control of the development program, including all costs going forward. Regulus will receive $7M upfront and is entitled to $40M in development milestone payments. Regulus had suspended enrollment in the Phase 2 RG-012 program in Alport Syndrome earlier this year in order to conserve cash while renegotiating terms with Sanofi. The transaction extends cash to 2Q19, but under new terms, Regulus will not be receiving any revenue from the program after Phase 2 is completed by Sanofi." (11/6/2018)
- 3. Wedbush analysts commented, "We believe this move will likely create some investor/analyst churn in the near term but will open up capital allocation and capacity to focus on the growing CHCA and CHCI segments in the longer term. Although the sale will likely take a couple quarters to complete, we believe this shift will attract a more consumer focused investor base lead to upside from the weak share performance following the report. As such, we remain BUY rated on PRGO shares." (8/10/2018)
Has Regulus Therapeutics been receiving favorable news coverage?
Press coverage about RGLS stock has trended somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regulus Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the stock's share price in the near term.
Who are some of Regulus Therapeutics' key competitors?
Some companies that are related to Regulus Therapeutics include Aerpio Pharmaceuticals (ARPO), Leap Therapeutics (LPTX), Novus Therapeutics (NVUS), Helix Biopharma (HBPCF), DiaMedica Therapeutics (DMAC), Celsion (CLSN), Moleculin Biotech (MBRX), ProPhase Labs (PRPH), AzurRx BioPharma (AZRX), MOTIF BIO PLC/S (MTFB), ContraFect (CFRX), Oncomed Pharmaceuticals (OMED), Aptevo Therapeutics (APVO), Novan (NOVN) and Achaogen (AKAO).
What other stocks do shareholders of Regulus Therapeutics own?
Who are Regulus Therapeutics' key executives?
Regulus Therapeutics' management team includes the folowing people:
- Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)
- Mr. Daniel R. Chevallard, Chief Financial Officer (Age 39)
- Dr. Timothy Michael Wright, Chief R&D Officer (Age 63)
- Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.
- Mr. Turner Jenkins, Director & Head of Corp. Devel.
Who are Regulus Therapeutics' major shareholders?
Regulus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (10.47%), BlackRock Inc. (0.56%), Geode Capital Management LLC (0.46%), Geode Capital Management LLC (0.46%) and Wedbush Securities Inc. (0.37%). Company insiders that own Regulus Therapeutics stock include Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.
Which institutional investors are selling Regulus Therapeutics stock?
RGLS stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Regulus Therapeutics.
How do I buy shares of Regulus Therapeutics?
Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regulus Therapeutics' stock price today?
One share of RGLS stock can currently be purchased for approximately $1.08.
How big of a company is Regulus Therapeutics?
Regulus Therapeutics has a market capitalization of $11.60 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis. Regulus Therapeutics employs 25 workers across the globe.
What is Regulus Therapeutics' official website?
How can I contact Regulus Therapeutics?
Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]
MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
